Pilosidine

CAS No. 229971-57-7

Pilosidine( —— )

Catalog No. M31831 CAS No. 229971-57-7

Pilosidine has vasoconstrictor activity, it showed facilitating effect on adrenaline evoked contractions in rabbit aorta isolated preparations.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 810 In Stock
50MG Get Quote In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Pilosidine
  • Note
    Research use only, not for human use.
  • Brief Description
    Pilosidine has vasoconstrictor activity, it showed facilitating effect on adrenaline evoked contractions in rabbit aorta isolated preparations.
  • Description
    Pilosidine has vasoconstrictor activity, it showed facilitating effect on adrenaline evoked contractions in rabbit aorta isolated preparations.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    229971-57-7
  • Formula Weight
    478.5
  • Molecular Formula
    C23H26O11
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Neuromedin U, rat

    Neuromedin U,a 23-amino acid brain-gut peptide, regulates several important physiological functions through its cognate receptor NMUR2 in the central nervous system, including energy balance, stress response, and nociception.

  • PLH1215

    PLH1215 is an effective AHR inhibitor that can be used to modulate, limit, or suppress the expression of AVIL (advillin). PLH1215 can be employed for the prevention and treatment of cancer.

  • Icosabutate

    Icosabutate (NST-4016) is an orally active derivative of eicosapentaenoic acid that inhibits hepatic inflammation and fibrosis in NASH, improves cardiovascular risk profiles in statin-treated patients with residual hypertriglyceridemia, lowers triglycerides, and may be useful in studies of liver fibrosis and atherosclerosis.